

## Chemically Enhanced Antisense Oligonucleotides: A Molecular Approach for Treating Autosomal Dominant Tubulointerstitial Kidney

S. Sjöström<sup>1</sup>, J. Lake<sup>2</sup>, M. Mariniello<sup>2</sup>, G. Schiano<sup>2</sup>, A. Kokanovic<sup>2</sup>, A. Hill<sup>1</sup>, O. Devuyst<sup>2</sup>, J. Hall<sup>1\*</sup>

<sup>1</sup>Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zürich, Switzerland, <sup>2</sup>Institute of Physiology, University of Zurich, Switzerland

Uromodulin, a predominant urinary protein, is produced by epithelial cells of the thick ascending limb (TAL) in the renal nephrons<sup>1,2</sup>. Mutations in the *Umod* gene, responsible for uromodulin production, can lead to autosomal dominant tubulointerstitial kidney disease (ADTKD) – a prevalent hereditary cause of progressive chronic kidney disease with limited treatment options<sup>3-5</sup>. To tackle this problem, we constructed a chemically enhanced antisense oligonucleotide (ASO) library to inhibit the translation of *Umod* mRNA and prevent its toxic accumulation. The design of our gapmer ASOs focused on two targets: the wild type (wt) sequence and a single nucleotide polymorphism (SNP) associated with severe ADTKD. The wt-targeting library is formulated to decrease overall uromodulin levels, providing a broad-spectrum approach to treat known ADTKD-UMOD cases. On the other hand, the SNP-targeting library aims to serve as a precision molecular tool to study SNP-discrimination and allele-selective oligonucleotide therapies, although with a narrower therapeutic scope. We identified a lead ASO that selectively silences an adverse disease-causing SNP (R185S) in vitro. Additionally, in vivo investigations into the ASO's silencing potency and bio-distribution were conducted post-subcutaneous administration in mice. Results show a promising uptake into the TAL cells and moderate silencing of *Umod* mRNA. This study demonstrates the potential for Umod as a molecular target of therapy and the TAL cells as a site of accumulation for this class of drugs.

[1] Tokonami, N. *et al.* Uromodulin is expressed in the distal convoluted tubule, where it is critical for regulation of the sodium chloride cotransporter NCC. *Kidney Int.* **94**, 701–715 (2018).

[2] Schaeffer, C., Devuyst, O. & Rampoldi, L. Uromodulin: Roles in Health and Disease. *Annu. Rev. Physiol.* **83**, 477–501 (2021).

[3] Gast, C. *et al.* Autosomal dominant tubulointerstitial kidney disease-UMOD is the most frequent non polycystic genetic kidney disease. *BMC Nephrol.* 2018 191 **19**, 1–11 (2018).

[4] Devuyst, O. *et al.* Autosomal dominant tubulointerstitial kidney disease. *Nature Reviews Disease Primers* vol. 5 1–20 (2019).

[5] Devuyst, O. & Pattaro, C. The UMOD locus: Insights into the pathogenesis and prognosis of kidney disease. *Journal of the American Society of Nephrology* vol. 29 713–726 (2018).